Multiple myeloma: biology, standard therapy, and transplant therapy.

about

Combination of IFN-α/Gm-CSF as a Maintenance Therapy for Multiple Myeloma Patients After Autologous Stem Cell Transplantation (ASCT): A Prospective Phase II Study.Translation initiation factor eIF4F modifies the dexamethasone response in multiple myeloma

P2860

Q33393257-65141574-FA05-426F-A69E-0B59CA7D4FC5 Q34218069-8F428318-4955-4DF1-A65A-52EAF4E0A350

P2860

Multiple myeloma: biology, standard therapy, and transplant therapy.

Item

http://www.wikidata.org/entity/Q42794048

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Multiple myeloma: biology, standard therapy, and transplant therapy.

@en

Multiple myeloma: biology, standard therapy, and transplant therapy.

@nl

type

Item

label

Multiple myeloma: biology, standard therapy, and transplant therapy.

@en

Multiple myeloma: biology, standard therapy, and transplant therapy.

@nl

prefLabel

Multiple myeloma: biology, standard therapy, and transplant therapy.

@en

Multiple myeloma: biology, standard therapy, and transplant therapy.

@nl

P1476

Multiple myeloma: biology, standard therapy, and transplant therapy.

@en

P2093

Irene Ghobrial

http://www.w3.org/2001/XMLSchema#string

Jean Luc-Harousseau

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2008

Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network

Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

Multiple myeloma.

A comparison of allografting with autografting for newly diagnosed myeloma.

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

Advances in biology of multiple myeloma: clinical applications.

Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma

Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

P304

46-52

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BBMT.2008.10.006

http://www.w3.org/2001/XMLSchema#string

P433

1 Suppl

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Morie A Gertz

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23952122

http://www.w3.org/2001/XMLSchema#string

P698

19147078

http://www.w3.org/2001/XMLSchema#string

P932

3133635

http://www.w3.org/2001/XMLSchema#string

Multiple myeloma: biology, standard therapy, and transplant therapy.

about

P2860

P2860

Multiple myeloma: biology, standard therapy, and transplant therapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932